Orthocell's Remplir™ Delivers Nerve Repair in Ukraine Combat Trauma

Why It Matters

The successful field use and regulatory clearance give OrthoCell a competitive edge in regenerative medicine, opening sizable defense and U.S. hospital markets for its next‑generation nerve‑repair technology.

Key Takeaways

• OrthoCell treated 23 Ukrainian soldiers with Remplir™ nerve repair.
• Product shipped without cold chain, enabling remote surgeon training.
• FDA approved in May 2023; US market expansion underway.
• Remplir™ outperforms 20‑year-old collagen wraps significantly in usability.
• Company pursuing 73 value analysis submissions to drive hospital adoption.

Summary

OrthoCell announced that its Remplir™ nerve‑repair product was used to treat Ukrainian combat casualties, marking the first humanitarian deployment of the technology in a war zone.

The company reported 23 soldiers treated—20 with post‑injury nerve damage and three with acute trauma—using a lightweight, non‑temperature‑controlled wrap that can be shipped globally. Surgeons were trained remotely by Australian KOL Dr. Alex O'Byrne, demonstrating the product’s logistical simplicity and rapid adoption.

CEO Paul Anderson highlighted Remplir™ as “extraordinary” and a “bioactive chamber” that reduces surgical time and delivers more predictable outcomes compared with legacy collagen wraps that are 20‑25 years old. FDA clearance was secured in May 2023, and OrthoCell is now scaling sales through U.S. key opinion leaders and hospital value‑analysis committees.

The deployment underscores OrthoCell’s potential to secure defense contracts and accelerate U.S. market penetration, positioning the firm for significant revenue growth as it fills a 73‑submission pipeline and expands beyond Australia.

Original Description

Orthocell Ltd managing director Paul Anderson talked with Proactive about the company’s Remplir™ nerve repair device and its recent real-world application in treating Ukrainian soldiers in combat. The company reported that Remplir™ has now been used in 23 surgical procedures, primarily addressing trauma-related nerve damage sustained on the battlefield.

Anderson explained that 20 of these cases involved post-injury trauma to damaged nerves, with the company receiving “such positive feedback from the Ukrainian military” following the treatments.

With a growing pipeline of hospital approvals and increasing adoption, Orthocell is positioning Remplir™ as a next-generation solution in regenerative medicine, offering more consistent and predictable clinical outcomes.

For more videos like this, visit the Proactive YouTube channel, give this video a like, subscribe, and enable notifications so you never miss an update.

#Orthocell #Remplir #Biotech #RegenerativeMedicine #NerveRepair #HealthcareInnovation #ASX #MedicalDevices #TraumaCare #USHealthcare #FDAApproval #BiotechInvesting #Ukraine #SurgicalInnovation #LifeSciences